135 related articles for article (PubMed ID: 32631540)
21. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
[TBL] [Abstract][Full Text] [Related]
22. Novel ALK5 inhibitor TP0427736 reduces TGF-β induced growth inhibition in human outer root sheath cells and elongates anagen phase in mouse hair follicles.
Naruse T; Aoki M; Fujimoto N; Arase S; Oura H; Ueda Y; Ikeda A
Pharmacol Rep; 2017 Jun; 69(3):485-491. PubMed ID: 28324846
[TBL] [Abstract][Full Text] [Related]
23. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of novel 2-(4-(1H-indazol-6-yl)-1H-pyrazol-1-yl)acetamide derivatives as potent VEGFR-2 inhibitors.
Wang XR; Wang S; Li WB; Xu KY; Qiao XP; Jing XL; Wang ZX; Yang CJ; Chen SW
Eur J Med Chem; 2021 Mar; 213():113192. PubMed ID: 33493829
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Krishnaiah M; Jin CH; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2015 Nov; 25(22):5228-31. PubMed ID: 26483198
[TBL] [Abstract][Full Text] [Related]
26. 2D-QSAR study, molecular docking, and molecular dynamics simulation studies of interaction mechanism between inhibitors and transforming growth factor-beta receptor I (ALK5).
Jiang MN; Zhou XP; Sun DR; Gao H; Zheng QC; Zhang HX; Liang D
J Biomol Struct Dyn; 2018 Nov; 36(14):3705-3717. PubMed ID: 29064324
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors.
Cho SY; Lee BH; Jung H; Yun CS; Ha JD; Kim HR; Chae CH; Lee JH; Seo HW; Oh KS
Bioorg Med Chem Lett; 2013 Dec; 23(24):6711-6. PubMed ID: 24210504
[TBL] [Abstract][Full Text] [Related]
28. Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).
Degorce SL; Boyd S; Curwen JO; Ducray R; Halsall CT; Jones CD; Lach F; Lenz EM; Pass M; Pass S; Trigwell C
J Med Chem; 2016 May; 59(10):4859-66. PubMed ID: 27078757
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Sreenu D; Krishnaiah M; Subrahmanyam VB; Rao KS; Nagendra Mohan AV; Park CY; Son JY; Son DH; Park HJ; Sheen YY; Kim DK
Eur J Med Chem; 2011 Sep; 46(9):3917-25. PubMed ID: 21696866
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5).
Guo C; Zhang C; Li X; Li W; Xu Z; Bao L; Ding Y; Wang L; Li S
Bioorg Med Chem Lett; 2013 Nov; 23(21):5850-4. PubMed ID: 24055046
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia.
Amada H; Asanuma H; Koami T; Okada A; Endo M; Ueda Y; Naruse T; Ikeda A
Chem Pharm Bull (Tokyo); 2013; 61(3):286-91. PubMed ID: 23449197
[TBL] [Abstract][Full Text] [Related]
32. ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles.
Řezníčková E; Tenora L; Pospíšilová P; Galeta J; Jorda R; Berka K; Majer P; Potáček M; Kryštof V
Eur J Med Chem; 2017 Feb; 127():632-642. PubMed ID: 28135685
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors.
Liu N; Wang Y; Huang G; Ji C; Fan W; Li H; Cheng Y; Tian H
Bioorg Chem; 2016 Apr; 65():146-58. PubMed ID: 26950400
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
Laping NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA
Mol Pharmacol; 2002 Jul; 62(1):58-64. PubMed ID: 12065755
[TBL] [Abstract][Full Text] [Related]
35. Functional targeting of the TGF-βR1 kinase domain and downstream signaling: A role for the galloyl moiety of green tea-derived catechins in ES-2 ovarian clear cell carcinoma.
Sicard AA; Suarez NG; Cappadocia L; Annabi B
J Nutr Biochem; 2021 Jan; 87():108518. PubMed ID: 33017609
[TBL] [Abstract][Full Text] [Related]
36. Tgf-beta type I receptor (Alk5) kinase inhibitors in oncology.
Ling LE; Lee WC
Curr Pharm Biotechnol; 2011 Dec; 12(12):2190-202. PubMed ID: 21619541
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.
Han SY; Choi JW; Yang J; Chae CH; Lee J; Jung H; Lee K; Ha JD; Kim HR; Cho SY
Bioorg Med Chem Lett; 2012 Apr; 22(8):2837-42. PubMed ID: 22450128
[TBL] [Abstract][Full Text] [Related]
39. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
Inman GJ; Nicolás FJ; Callahan JF; Harling JD; Gaster LM; Reith AD; Laping NJ; Hill CS
Mol Pharmacol; 2002 Jul; 62(1):65-74. PubMed ID: 12065756
[TBL] [Abstract][Full Text] [Related]
40. A Highly Selective Chemical Probe for Activin Receptor-like Kinases ALK4 and ALK5.
Hanke T; Wong JF; Berger BT; Abdi I; Berger LM; Tesch R; Tredup C; Bullock AN; Müller S; Knapp S
ACS Chem Biol; 2020 Apr; 15(4):862-870. PubMed ID: 32176847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
